Therapeutics News and Research

RSS

Affimed Therapeutics reports additional results from AFM13 phase 1 study on R/R Hodgkin lymphoma

Affimed Therapeutics AG announced today further results from its phase 1 clinical trial of AFM13 as monotherapy for the treatment of patients with advanced relapsing/refractory (R/R) Hodgkin lymphoma.

10 Apr 2014

Osiris Therapeutics receives $15 million cash payment from Mesoblast for Prochymal

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets, announced that it has received the next $15 million cash payment from Mesoblast in accordance with the Purchase Agreement relating to the Prochymal business.

9 Apr 2014

Spero Therapeutics enters into antibiotics partnership with Roche

Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for treatment of bacterial infections, has entered into an antibiotics partnership with Roche.

9 Apr 2014

Research shows blocking DNA repair improves radiation therapy for glioblastomas

UT Southwestern Medical Center researchers have demonstrated in both cancer cell lines and in mice that blocking critical DNA repair mechanisms could improve the effectiveness of radiation therapy for highly fatal brain tumors called glioblastomas.

9 Apr 2014

ImmunoGen presents first findings aimed at optimizing dosage of IMGN853 product candidate

ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the first findings from Company research aimed at optimizing the dosing of its IMGN853 product candidate.

9 Apr 2014

Researchers identify novel compound effective against drug-resistant lung cancer

Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer's ability to resist treatment, rendering the chemotherapy ineffective.

9 Apr 2014

MicroBiome Therapeutics to present clinical trial data of NM504 in type 2 diabetes, prediabetes at ICE/ENDO 2014

MicroBiome Therapeutics LLC, today announced that data from the company's clinical trial of microbiome modulator NM504 in development for type 2 diabetes and prediabetes has been accepted for a Poster Preview Presentation at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and The Endocrine Society.

8 Apr 2014

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

PeptiDream Inc., a public Tokyo-based biopharmaceutical company ("PeptiDream")( TOKYO:4587) announced today, in collaboration with The Tokyo Metropolitan Institute of Medical Science ("Tokyo Metropolitan Institute") the discovery and development of a novel macrocyclic peptide inhibitor for the treatment of multiple influenza strains.

8 Apr 2014

Research suggests NEDD9 scaffolding protein activates oncogenic signaling pathways in cancer cells, encourages metastases

Researchers from Fox Chase Cancer Center have shown that NEDD9, a scaffolding protein responsible for regulating signaling pathways in the cell, promotes the growth and spread of epithelial ovarian cancer.

7 Apr 2014

Researchers demonstrate accurate identification of amino acids

Some three billion base pairs make up the human genome-the floor plan of life. In 2003, the Human Genome Project announced the successful decryption of this code, a tour de force that continues to supply a stream of insights relevant to human health and disease.

7 Apr 2014

Research provides new approach to developing better treatment options for scleroderma

Scleroderma is a rare and often fatal disease, causing the thickening of tissue, that currently lacks a cure and any effective treatments. A group of researchers, including a Michigan State University professor, is looking to change that.

7 Apr 2014

FDA approves expanded use Dyax’s KALBITOR in treatment of acute hereditary angioedema

Dyax Corp. today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for KALBITOR (ecallantide), a peptide inhibitor of plasma kallikrein used in the treatment of acute hereditary angioedema (HAE) attacks, to include patients 12 years of age and older.

4 Apr 2014

Harvard stem cell scientists discover potential treatment for amyotrophic lateral sclerosis

Harvard stem cell scientists have discovered that a recently approved medication for epilepsy may possibly be a meaningful treatment for amyotrophic lateral sclerosis (ALS)-Lou Gehrig's disease, a uniformly fatal neurodegenerative disorder. The researchers are now collaborating with Massachusetts General Hospital to design an initial clinical trial testing the safety of the treatment in ALS patients.

4 Apr 2014

UCSF/Daiichi Sankyo establish drug-discovery collaboration focused on neurodegenerative diseases

Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) and UC San Francisco (UCSF) announced today that they have established a drug-discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases.

4 Apr 2014

Accele Venture Partners co-led $4.1M Series A private equity financing of Otologic Pharmaceutics

Accele Venture Partners, the investing arm of life sciences accelerator Accele Biopharma, Inc., announced today that it has co-led a $4.1 million Series A private equity financing of Otologic Pharmaceutics, Inc. (OPI), a development-stage biopharmaceutical company committed to developing and commercializing novel pharmacological solutions and approaches to treat hearing disorders.

3 Apr 2014

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Omeros Corporation today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement‑mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration.

3 Apr 2014

Crescendo raises additional £2M ($3.3M) in final close of Series A financing from EMBL Ventures

Crescendo Biologics Limited today announces it has raised a further £2m ($3.3m), from EMBL Ventures, in a final close of its Series A financing. Originally announced in December 2013, the Series A now totals £19.5m. It was led by Imperial Innovations and included new investor Astellas Venture Management. Founding seed investor Sofinnova Partners also contributed significantly to the round.

3 Apr 2014

Clinical Therapeutics features a special report on trans fat

Clinical Therapeutics features a special report in its March issue focusing on the science and policy leading up to the US Food and Drug Administration's (FDA) preliminary steps toward restricting industrially produced trans fatty acids, or trans fat, at the federal level.

3 Apr 2014

Findings may help develop targeted drugs to fight cancer, neurodegenerative diseases

The molecular details of how zinc, an essential trace element of human metabolism, interacts with the enzyme caspase-3, which is central to apoptosis or cell death, have been elucidated in a new study led by researchers at Virginia Commonwealth University. The study is featured on the cover of the April issue of the journal Angewandte Chemie's International Edition.

3 Apr 2014

JPIAMR outlines steps to minimise antimicrobial resistance

Antibiotics have saved millions of lives from once deadly infectious diseases. But, misuse of antibiotics and other antimicrobials in humans and animals has led to bacteria evolving resistance.

3 Apr 2014

Therapeutics News and Research

Affimed Therapeutics reports additional results from AFM13 phase 1 study on R/R Hodgkin lymphoma

Osiris Therapeutics receives $15 million cash payment from Mesoblast for Prochymal

Spero Therapeutics enters into antibiotics partnership with Roche

Research shows blocking DNA repair improves radiation therapy for glioblastomas

ImmunoGen presents first findings aimed at optimizing dosage of IMGN853 product candidate

Researchers identify novel compound effective against drug-resistant lung cancer

MicroBiome Therapeutics to present clinical trial data of NM504 in type 2 diabetes, prediabetes at ICE/ENDO 2014

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

Research suggests NEDD9 scaffolding protein activates oncogenic signaling pathways in cancer cells, encourages metastases

Researchers demonstrate accurate identification of amino acids

Research provides new approach to developing better treatment options for scleroderma

FDA approves expanded use Dyax’s KALBITOR in treatment of acute hereditary angioedema

Harvard stem cell scientists discover potential treatment for amyotrophic lateral sclerosis

UCSF/Daiichi Sankyo establish drug-discovery collaboration focused on neurodegenerative diseases

Accele Venture Partners co-led $4.1M Series A private equity financing of Otologic Pharmaceutics

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Crescendo raises additional £2M ($3.3M) in final close of Series A financing from EMBL Ventures

Clinical Therapeutics features a special report on trans fat

Findings may help develop targeted drugs to fight cancer, neurodegenerative diseases

JPIAMR outlines steps to minimise antimicrobial resistance

Understanding the DNA Damage Response in Innate Immunity eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News